Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
View abstract on PubMed
Summary
This summary is machine-generated.Identifying clinical factors associated with long-term response and survival in BRAF-mutant melanoma patients treated with dabrafenib plus trametinib is crucial. Patients with normal lactate dehydrogenase (LDH) and fewer metastases had significantly longer progression-free and overall survival.
Area Of Science
- Oncology
- Medical Genetics
- Pharmacology
Background
- Dabrafenib plus trametinib offers benefits over BRAF-inhibitor monotherapy for advanced melanoma.
- Disease progression remains a challenge, necessitating identification of predictive factors for long-term response and survival.
- Optimizing patient management requires understanding clinical predictors for targeted therapy in BRAF-mutant melanoma.
Purpose Of The Study
- To identify clinical factors associated with long-term response and survival in patients with metastatic BRAF-mutant melanoma treated with dabrafenib plus trametinib.
- To analyze pooled data from randomized trials to determine predictors of progression-free survival (PFS) and overall survival (OS).
Main Methods
- Retrospective analysis of individual patient data from randomized trials (BRF113220, COMBI-d, COMBI-v).
- Inclusion of treatment-naive patients with BRAF V600E/K-mutant metastatic melanoma receiving dabrafenib plus trametinib.
- Analysis of baseline factors, on-treatment factors, and post-progression factors for association with PFS and OS using univariate, multivariate, and regression tree analyses.
Main Results
- 617 patients were analyzed with a median follow-up of 20.0 months.
- Patients with normal lactate dehydrogenase (LDH) and fewer than three metastatic organ sites exhibited the longest PFS and OS.
- Patients with LDH ≥ 2x upper limit of normal had significantly shorter PFS and OS.
- Survival after progression was shortest for patients with new central nervous system (CNS) lesions or concurrent progression in baseline and new lesions.
Conclusions
- Several baseline and on-treatment clinical characteristics predict outcomes for dabrafenib plus trametinib therapy.
- Durable benefit from targeted therapy is achievable in specific patient subsets.
- Identification of prognostic factors can aid in optimizing treatment strategies for metastatic melanoma.